EVALUATION OF PATHOLOGIC COMPLETE RESPONSE (PCR) RATE IN PATIENTS WITH NEOADJUVANT CHEMOTHERAPY RELATED TO IMMUNOHISTOCHEMICAL CHARACTERISTICS.

INABA, L. A. (Instituto do Câncer Dr. Arnaldo Vieira de Carvalho), BASTOS, E. A. (Instituto do Câncer Dr. Arnaldo Vieira de Carvalho), RODRIGUES, F. F. O. (Instituto do Câncer Dr. Arnaldo Vieira de Carvalho), SILVA, R. M. (Instituto do Câncer Dr. Arnaldo

Instituto do Câncer Dr. Arnaldo Vieira de Carvalho (ICAVC)To determine tumoral immunohistochemistry as a predictive factor for pathologic complete response (pCR) rate from patients with breast cancer treated with neoadjuvant chemotherapy. A retrospective database analysis from our service in patients with breast cancer treated at our institution (ICAVC) during 08/31/2006 and 01/10/2010 with follow up until 01/12/2016. A total of 106 patients with invasive breast cancer SOE were included in the study, and 32 (30,2%) received neoadjuvant chemotherapy based on anthracycline and taxane. There were five (15,6%) patients who achieved pCR (defined as the absence of residual invasive cancer in breast and lymph nodes in surgical specimens after neoadjuvant therapy), and only immunohistochemically defined as luminal B did not present pCR. The patients who achieved pCR were divided in 7% luminal A, 20% triple-negative (TN), and 28% luminal-Her, according to molecular biomarkers. In the setting of neoadjuvant chemotherapy patients with breast cancer subtype compatible to luminal-Her had better pCR rates, followed by TN patients which demonstrated more specificity treatment in the systemic therapy. On the other hand, we observed that patients luminal B presented resistance to the neoadjuvant treatment translated by the absence of pCR.breast cancer, neoadjuvant chemotherapy, pathologic complete response